Torrent Pharma to acquire Glochem’s Visakhapatnam facility

The Dollar Business Bureau

Ahmedabad-based Torrent Pharma announced that it signed a deal to take over the Glochem Industries’ Visakhapatnam facility.

The Pharmaceutical firm broke the news on Thursday. However, the firm did not disclose the value agreed in the deal.

Torrent, in a regulatory filing, said that an agreement has been inked to purchase the manufacturing plant of Glochem with some Drug Master Files. API manufacturing facility of Visakhapatnam belongs to Hyderabad-based Glochem.

The purchase of the plant will not only help Torrent to beef up the manufacturing capacity and meet global demand, but also meet the backward integration of its Abbreviated New Drug Application, said Jinesh Shah, Torrent Pharma Executive Director (Operations). ANDA is the filing undertaken by a pharma firm in a bid to sell the generic version of its product.

DMF is a confidential document containing in-depth details about controls and manufacturing, processing, storage of a drug component and chemistry. It is submitted to the US Food and Drug Administration by Active Pharmaceutical Ingredient. With the purchase of Glochem’s facility, Torrent, which has about five formulation manufacturing facilities, will have three API producing units for the regulatory market.

The Vishakapatnam facility, approved by the European regulatory authority and USFDA, is a multi-product unit. It bears capacity to manufacture APIs and advanced intermediaries. It has three blocks for advanced intermediate manufacturing and four for APIs. It is also capable for quality control laboratory, analytical method development, site development and a pilot plant.